Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAT1 | P18440 | 3/20 | 0.35 |
| ▸ | UNG | P13051 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25812882 | 0.83 | ELANE (0.39) | ALDH1A1CA1CA2CA9MAPT | |
| SCHEMBL25812739 | 0.81 | NAT1 (0.38) | NAT1ALDH1A1CA12CA1CA2 | |
| SCHEMBL25811432 | 0.80 | HTR6 (0.36) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL25811421 | 0.76 | PTGS2 (0.46) | CA12CA1CA2CA9MAPT | |
| SCHEMBL16383945 | 0.66 | ELANE (0.42) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL2538638 | 0.62 | HTR6 (0.56) | NAT1UNGALDH1A1CA12CA1 | |
| SCHEMBL11735462 | 0.61 | PSIP1 (0.52) | NAT1UNGALDH1A1CA12CA1 | |
| SCHEMBL2324277 | 0.61 | ALDH1A1 (0.43) | ALDH1A1TTRKMT2ACYP2A6KDM4E | |
| SCHEMBL41941 | 0.60 | CA12 (0.47) | NAT1UNGALDH1A1CA12CA1 | |
| SCHEMBL30402657 | 0.60 | CA12 (0.47) | NAT1UNGALDH1A1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | GALYAN BIO INC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | HTT, HYPK, PARK7 | NAT1 127/4885UNG 1687/4885ALDH1A1 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.